Coherus Promises ‘Compelling Value Proposition’ After US Adalimumab Approval
Yusimry Biosimilar To Humira Set For 1 July 2023 Launch, After Multiple Rivals
Executive Summary
As the likely dynamics for US biosimilar competition to Humira come into sharper focus, Coherus has promised that its mid-2023 market entry with its just-approved Yusimry version will be accompanied by a “compelling value proposition,” months after rival Amgen’s biosimilar is expected to launch and around the same time as multiple other rivals are expected to hit the market.
You may also be interested in...
Coherus Reveals US Launch Plans For Interchangeable Ranibizumab
Coherus has revealed further details of the firm’s plans for its Cimerli interchangeable biosimilar rival to Lucentis in the US, including a launch date and pricing information.
Coherus Shakes Up Ranibizumab Competition With First Interchangeable US Biosimilar
Coherus BioSciences has heralded a “strategic inflection point” for the company after receiving USFDA approval for Cimerli as an interchangeable biosimilar rival to Lucentis. The firm has also revealed launch plans for the Bioeq-partnered ranibizumab product.
Frontrunner Amgen Expects US Biosimilars To ‘Shift Significantly’ With Adalimumab
Amgen expects a significant shift in the US biosimilars landscape as Humira rivals launch next year, Chad Pettit, the firm’s executive director of marketing and global biosimilars lead, tells Generics Bulletin. The company expects to be first to market with its version of adalimumab from the end of January 2023, helping to drive long-term growth ambitions for its biosimilars business.